Klin Onkol 2016; 29(1): 13-19. DOI: 10.14735/amko201613.
Hormonal dependent breast cancer is a heterogeneous disease from a molecular and clinical
perspective. The relapse risk of early breast cancer patients treated with adjuvant hormonal
therapy varies. Validated predictive markers concerning adjuvant cytotoxic treatment are still
lacking in ER+/ HER2– breast cancer, which has a good prognosis in general. This can lead to the inefficient chemotherapy indication. Molecular classifi cation of breast cancer reports evidence about the heterogeneity of hormonal dependent breast cancer and its stratifi cation to diff erent groups with diff erent characteristics. Multigene assays work on the molecular level, and their aim is to provide patients’ risk stratifi cation and therapy effi cacy prediction. The position of multigene assays in clinical practice is not stabile yet. Non- uniform level of evidence connected to patients’ prognosis interpretations and diffi cult comparison of tests are the key problems, which prevent their wide clinical use. The article is a summary of some of the most important multigene assays in breast cancer and their current position in oncology practice.
